Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program

Radium-223, a targeted alpha therapy, is used to treat symptomatic patients with castration-resistant prostate cancer (CRPC) and bone metastases. Data for radium-223 in asymptomatic CRPC patients with bone metastases are lacking.